Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Licenses Gene Targeting Technology to AstraZeneca

NEW YORK, Dec. 22 (GenomeWeb News) - Lexicon Genetics has non-exclusively licensed to AstraZeneca the rights to its gene-targeting technologies for use in drug discovery research, the company said today.

 

The Woodlands, Texas company did not disclose the financial terms of the license which revolves around the company's patented technology for discovering gene function in vivo using knockout mice.

 

Aventis, Pfizer, GlaxoSmithKline, Merck, and Millennium Pharmaceuticals are among the other licensees of Lexicon's technology

 

This licensing deal comes on the heels of a $66 million drug discovery collaboration with Bristol-Myers Squibb, which the company announced last Friday.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.